NHS

#COPD #National Institute for Health and Care Excellence (NICE) #NHS

NICE recommends mepolizumab as COPD add-on treatment 

The National Institute for Health and Care Excellence (NICE) has recommended Nucala (mepolizumab) as an add-on treatment for NHS patients with COPD.  The draft final guidance recommends mepolizumab as an add-on maintenance treatment option for adult patients with uncontrolled COPD with raised blood eosinophils, if they are having… Read More

#News #Regulatory

Non-small cell lung cancer
#Lung cancer #National Institute for Health and Care Excellence (NICE) #NHS #Non-small cell lung cancer (NSCLC) #Regeneron Pharmaceuticals

NICE recommends lung cancer combination therapy 

The National Institute for Health and Care Excellence (NICE) has recommended cemiplimab in combination with platinum-based chemotherapy to treat patients with non-small cell lung cancer (NSCLC).  Cemiplimab is a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells, which was shown to block cancer cells from… Read More

#News #Regulatory

Histology slides
#Cyclana Bio #Endometriosis #NHS

Cyclana Bio gets green light to launch endometriosis trial 

Cyclana Bio has been granted Health Research Authority (HRA) and Research Ethics Committee (REC) approval by the NHS to launch a study into endometriosis.  The biotechnology company will now go ahead with its 500-patient clinical observational study, being called PEMP (Predicting Endometriosis Mechanisms and Populations), to improve understanding… Read More

#News #Regulatory

#Arthritis #Cancer research #Immune response #NHS #Oncology #Ovarian cancer #SynaptixBio #Tumour biology #UK government #University of Birmingham

DDW Highlights: 21 April 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, key breakthroughs emerged in cancer research. Elsewhere, regulatory reforms have accelerated clinical… Read More

#Podcasts

#Arthritis #Cancer research #Immune response #NHS #Oncology #Ovarian cancer #SynaptixBio #Tumour biology #UK government #University of Birmingham

This week in Drug Discovery (13 – 17 April) 

News round-up for 13 – 17 April by Bruno Quinney, Content Team at DDW.  This week, breakthroughs have emerged in cancer research. Elsewhere, regulatory reforms have accelerated clinical trial set up in the UK.  The top stories:    Novel therapy could slow tumour growth… Read More

#News

Clinical trial
#Clinical trials #NHS #UK government

Regulatory reforms accelerate UK clinical trial set up

NHS patients are accessing groundbreaking treatments faster as the UK government fulfils its promise for a 150-day clinical trial target.  The latest UK Clinical Research Delivery key performance indicators show the average time to set up a commercial interventional clinical trial has fallen from 169 days to 122 days when comparing the same six month period… Read More

#News #Regulatory

#ABPI #Clinical trials #GLP-1 #Immune response #NHS #Obesity #Oncology #Prostate cancer #T cell #Texas A&M University Health Science Center #Weight loss

DDW Highlights: 31 March 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates the key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a study found obesity could be treated in other ways than through drugs… Read More

#Podcasts

#ABPI #Clinical trials #Dementia #GLP-1 #Immune response #Neuroscience #NHS #Obesity #Oncology #Prostate cancer #T cell #Texas A&M University Health Science Center #Tregs #Weight loss

This week in Drug Discovery (23 – 27 March) 

News round-up for 23 – 27 March by Bruno Quinney, Content Team at DDW.  This week, obesity could be treated in other ways than through drugs suppressing appetite. Elsewhere, prostate cancer has been a central theme in cancer research.   The top stories:    Obesity… Read More

#News

#Bacteria #Blood cancer #Cancer Research UK #HaemaLogiX #Haematology #Institute of Cancer Research #Myeloma #Neuroscience #NHS #Oncology #Orphan drugs #Parkinson's #Rare diseases #University of Edinburgh

This week in Drug Discovery (16 – 20 March) 

News round-up for 16 – 20 March February by Bruno Quinney, Content Team at DDW.  This week, a pioneering method is being used to make drugs for Parkinson’s disease. Elsewhere, advances have been made in both research and trials for common cancers.  The top stories:    Edinburgh team… Read More

#News

Lilly Biotechnology Center
#Alzheimer's #Eli Lilly #National Institute for Health and Care Excellence (NICE) #NHS

Lilly wins appeal for donanemab, drug to be reconsidered for NHS 

Eli Lilly’s appeal against guidance which did not recommend donanemab has been upheld, forcing authorities to reconsider the drug for NHS use.  The National Institute for Health and Care Excellence (NICE) published the outcome for Lilly’s appeal, after final draft guidance had not recommended NHS reimbursement of donanemab for the treatment of mild cognitive… Read More

#News

Blood cancer
#Blood cancer #Cancer Research UK #NHS

First patient dosed in ROR1-positive blood cancer treatment 

The first patient has been dosed in a treatment for ROR1-positive blood cancers.  NVG-222 is a bispecific T-cell engager targeting ROR1 and CD3, developed by biotechnology company NovalGen.  The drug is the first therapeutic candidate to use NovalGen’s proprietary AutoRegulation technology, an innovation designed to mitigate excessive… Read More

#Cancer Research #News

Europe
#Arthritis #Biosimilars #Europe #NHS #Ulcerative colitis (UC)

Alvotech launches Simponi biosimilar in Europe 

Biotechnology company Alvotech has announced the European launch of its first-in-market biosimilar to Simponi (golimumab).  AVT05, known as Gobivaz, is a prefilled syringe and autoinjector used for the treatment of adults with rheumatoid arthritis, psoriatic arthritis and ulcerative colitis, as well as in children with ulcerative colitis. Gobivaz becomes the first marketed biosimilar to… Read More

#News

Cell and gene therapy
#Advanced Therapies #Cell and gene therapy #Drug development #NHS

eXmoor and NHS trust partner on cell & gene therapies 

Cell and gene therapy CDMO eXmoor Pharma has partnered with Royal Free London NHS Foundation Trust to collaborate on the development and manufacturing of cell and gene therapies in the UK. The collaboration brings together eXmoor’s later-phase clinical manufacturing capabilities  with the trust’s Cell and Vector Innovation Centre (CVIC), which… Read More

#Business & Investment #News

Protesting against health inequalities
#ABPI #NHS #UK government #US government

UK-US trade deal good news for UK life sciences, ABPI says 

The UK-US trade agreement is good news for NHS patients and will support the UK life sciences industry, the Association of the British Pharmaceutical Industry (ABPI) says.  The agreement will ensure that UK pharmaceutical exports to the US continue to face 0% tariffs for three years. In… Read More

#News

Multiple myeloma
#Myeloma #National Institute for Health and Care Excellence (NICE) #NHS

NICE recommends myeloma treatment for NHS patients

The National Institute for Health and Care Excellence (NICE) has recommended Talvey (talquetamab) for use in the NHS for treating relapsed or refractory myeloma (RRMM) in adults.  Talquetamab, developed by Johnson & Johnson, is a first-in-class bispecific antibody targeting the GPRC5D receptor on myeloma cells. The treatment… Read More

#News #Regulatory

#Collaboration #Genomics #Genomics England #NHS #Public health #Research #Revvity

Collaboration to advance UK genomics research 

Revvity has announced an expansion of its working relationship with Genomics England that leverages both organisations’ expertise and resources to advance critical genomic initiatives across the United Kingdom.   Building on the parties’ long and productive work history, this collaboration is dedicated to accelerating Genomics England’s research programmes,… Read More

#Business & Investment #News